2023-508531-30-00招募中2 期
A randomized and controlled phase II protocol in non NF1 pediatric and AYA (Adolescent and Young Adults) patients bearing a newly diagnosed low grade glioma with wild type BRAF gene comparing a daily oral MEK inhibitor (Trametinib) versus weekly vinblastine for 18 months. PLGG – MEKTRIC (Pediatric Low Grade Glioma – MEKinhibitor TRIal vs Chemotherapy)
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 134
- 试验地点
- 25
- 主要终点
- Therefore, our primary endpoint is the 3-year PFS rates comparing the two arms (standard vs experimental). The analysis will be based on PFS measured from time of 1st treatment administration up to the first event during the first 3 years of follow-up. An event is defined as death for all reasons, progression of a residual tumor, reappearance of a tumor in case of disappearance and/or appearance of new locations in the brain and spine.
研究概览
简要总结
improve the current standard treatment regimen expecting a superiority of the experimental arm (e.g. MEK inhibitor, daily Trametinib (Mekinist©)) vs standard therapy (e.g. weekly IV Vinblastine) during a length of 18 courses (4 weeks each, a total of 72 weeks) in the group of non-NF1 PLGGs, characterized by a wild-type BRAF gene. This expected superiority of the 3-year PFS is estimated to 20%.
入排标准
- 年龄范围
- 0 years 至 64 years（0-17 Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Age: ≥ 1 month to ≤ 25 years
- •Sus-tentorial, optic pathway, midline and spine locations allowed
- •Karnofsky or Lansky ≥ 50%
- •Criteria for post-surgical treatment: severe visual or neurological symptoms at diagnosis, clinical deterioration of visual or neurological symptoms or radiological progression. The radiological progression is defined as an increase of solid part of the tumor of more than 25% compared to the pre-baseline MRI-imaging over a time period of at least 3 months or the occurrence of new metastatic lesions.
- •Infants below one year of age with chiasmatic and/or hypothalamic tumor will be treated immediately after surgery, independently from neurological and/or visual evolution
- •Females of child-bearing potential must be willing to practice highly effective contraception during all treatment and until 6 months after the last dose of study drugs’ administration. Additionally, females of child-bearing potential must have a negative serum pregnancy test within 7 days prior to start of study drugs. Boys with reproductive potential must be willing to use condom and consider contraception for partner women of childbearing potential during treatment and until 4 months after the last study drugs’ administration.
- •Patients must have adequate bone marrow function defined as: absolute neutrophil count (ANC) ≥ 1500/µL; platelets ≥ 100,000/µL and hemoglobin ≥ 9.0 g/dl
- •Patients must have adequate liver function within 7 days prior to screening: bilirubin (sum of unconjugated and conjugated) ≤ 1.5 ULN for age, ALT and AST ≤ 2.5 x upper limit of normal, alkaline phosphatase ≤ 4 x upper limit of normal, INR/PTT < 1.5 x upper limit of normal,
- •Patients must have adequate renal function within 7 days prior to screening: serum creatinine < 1.5 x upper limit of normal for age and a creatinine clearance > 60 ml/min for 1.73 m2
- •Cardiac function defined as a corrected QT (QTcF) interval < 480 msec, LVEF ≥ lower limit of normal (LLN) by echocardiogram (ECHO)
- •Adequate blood pressure control (smaller or equal to the 95th percentile for patient's age, height and gender)
- •Signed written informed consent prior to study participation of the legal representatives and the patient if the patient can understand the impact of clinical trial and to give consent. For patients above 18 years, their written informed consent will be obtained.
- •Patients are willing and able to comply with scheduled visits, treatment plan, laboratory tests and study procedures
- •Guardians (in case of patients under 18 years) or patient if above 18 years must be affiliated to or a beneficiary of health insurance system.
- •Patient may be under guardianship or curatorship (for patient under legal guardianship, authorization is given by the legal representative of the patient under guardianship. For patient under curatorship consent will be obtained from the adult assisted by his or her legal curator
- •Histologically proven grade 1 glioma/mixed glio-neuronal tumors or pleomorphic xanthoastrocytoma (PXA) confirmed by local referee and the centrally pathology reviewing
- •Determination of a negative BRAFv600 mutation by immunohistochemistry and/or molecular methods
- •Systematic determination 7q34 duplication status or KIAA1549-BRAF fusion
- •Midline tumors without proven histone H3 mutations
- •Diffuse glioma without IDH1 mutation
- •Collection of fresh frozen tumor tissues and/or paraffin-embedded samples for further molecular biomarker testing
排除标准
- •Patients presenting a neurofibromatosis type 1 (NF1) congenital disease
- •Participation in other clinical trials
- •Prior non-surgical therapy for this tumor
- •Diffuse intrinsic pontine glioma (DIPG), even if histologically diagnosed as WHO grade II
- •Subependymal giant astrocytoma (SEGA) in patients with TSC
- •Patients receiving government medical aid (Aide Médicale de l'Etat - AME)
- •Patient having a known diagnosis of human immunodeficiency virus (HIV) infection, hepatitis B or C
- •Known hypersensitivity to drugs or excipients
- •History of another malignancy
- •History of current uncontrolled infection
- •Pure optic nerve glioma, limited to one nerve and without optic chiasma infiltration.
- •Completely resected tumors
- •Previous treatment except tumor surgery
- •Pregnancy and lactation
结局指标
主要结局
Therefore, our primary endpoint is the 3-year PFS rates comparing the two arms (standard vs experimental). The analysis will be based on PFS measured from time of 1st treatment administration up to the first event during the first 3 years of follow-up. An event is defined as death for all reasons, progression of a residual tumor, reappearance of a tumor in case of disappearance and/or appearance of new locations in the brain and spine.
Therefore, our primary endpoint is the 3-year PFS rates comparing the two arms (standard vs experimental). The analysis will be based on PFS measured from time of 1st treatment administration up to the first event during the first 3 years of follow-up. An event is defined as death for all reasons, progression of a residual tumor, reappearance of a tumor in case of disappearance and/or appearance of new locations in the brain and spine.
次要结局
- • the tumor response at 24 and 72 weeks based on the international and recognized RANO criteria, the analysis comparing the 2 arms will be based on overall response rate (ORR) by central independent radiological review assessment. The analysis will be conducted in all patients at least at 24 weeks of completed treatment or earlier for the patients who have discontinued for progression reasons. The tumor response will classify the patients in 2 groups: PD subgroup versus CR/PR/SD subgroup.
- • the 3-year OS rate: the OS calculation will take into account the survival measured from time of 1st treatment administration up to death.
- • the frequency and description of AE (adverse event)/SAE (serious adverse event) based on CTCAE criteria (using NCI-CTCAE version 5.0) focusing on visual disturbances, skin, intestinal and cardiac side effects in the experimental arm compared with the standard control arm. The safety assessment will be done by cycle and by patient.
- • the QoL based on specific questionnaires (PEDs-QoL) at baseline, 24 weeks, at the end of treatment and 3 years after the first treatment administration. The analysis is based on EORTC adapted QOL questionnaires.
- • the 3-year PFS and OS rates according to molecular biomarkers obtained with routinely done molecular analyses (RENOCLIP-LOC platform) and after centralized review of each tumor histology.
- • the 3-year PFS and OS rates according to visual outcome in patient with optic pathway glioma with an analysis of visual function (LoqMAR scale) at baseline, at 24 weeks, at the end of treatment and after 3 years of treatment.
- • the data of patients benefiting from the crossover strategy will be collected to obtain information about response rate, PFS and OS for those patients progressing or relapsing on standard arm treatment.
研究者
Natacha ENTZ-WERLE
Scientific
Les Hopitaux Universitaires De Strasbourg
研究点 (25)
Loading locations...
相似试验
已完成
1 期
Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside TamoxifenBreast CancerNCT02285179The Netherlands Cancer Institute189
已完成
2 期
Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 YearsMeaslesNCT00891007Bavarian Nordic90
Unknown
2 期
Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the HumansCancerNCT02340845Oeyama-Moto Cancer Research Foundation100
已完成
2 期
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRPCoronary Heart DiseaseNCT06031844Novartis Pharmaceuticals24
已完成
2 期
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)Clonal Hematopoiesis of Indeterminate Potential (CHIP)Coronary Heart DiseaseNCT06097663Novartis Pharmaceuticals31